Format

Send to

Choose Destination
AIDS. 2006 Oct 3;20(15):1911-5.

Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody.

Author information

1
Swedish Institute for Infectious Disease Control, Microbiology and Tumor Biology Center, Karolinska Institutet, S-171 82 Solna, Sweden. susanne.johansson@smi.ki.se

Abstract

OBJECTIVE:

To test the efficacy of an immunoconjugate against HIV-1.

DESIGN:

: A murine monoclonal antibody against the envelope antigen of HIV (P4/D10) was conjugated with the conventional anticancer drug, doxorubicin, and tested against infectious virus and infected cells, both in vitro and in vivo.

METHODS:

P4/D10 antibody was incubated with free virus (neutralization) or HIV-infected cells (inhibition) and the resulting infection was measured by a p24 capture enzyme-linked immunosorbent assay. In an HIV-1/MuLV murine challenge model, the ability of the conjugate to inhibit infection in vivo was measured.

RESULTS:

Doxorubicin-conjugated P4/D10 neutralized HIV-1IIIB and eliminated intercellular spread and HIV replication in infected Jurkat cells in vitro. The conjugate also protected mice from challenge with HIV-1IIIB/MuLV at an eightfold lower concentration than needed for free antibody, whereas no effects were observed for comparable doses of free drug or irrelevant conjugate controls.

CONCLUSION:

This indicates that doxorubicin is concentrated to HIV-infected cells by the P4/D10 antibody, significantly (P = 0.0001) contributing to HIV elimination. This concept could also be adapted to eradicate remaining antigen-expressing T cells in patients treated with antiretroviral therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center